Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73*

p53 is the most frequently inactivated tumor suppressor gene in human cancer, whereas its homologue, p73, is rarely mutated. Similarly to p53, p73 can promote growth arrest or apoptosis when overexpressed in certain p53-null tumor cells. It has previously been shown that some human tumor-derived p53 mutants can exert gain of function activity. The molecular mechanism underlying this activity remains to be elucidated. We show here that human tumor-derived p53 mutants (p53His175 and p53Gly281) associate in vitro andin vivo with p73α, β, γ, and δ. This association occurs under physiological conditions, as verified in T47D and SKBR3 breast cancer cell lines. The core domain of mutant p53 is sufficient for the association with p73, whereas both the specific DNA binding and the oligomerization domains of p73 are required for the association with mutant p53. Furthermore, p53His175 and p53Gly281 mutants markedly reduce the transcriptional activity of the various isoforms of p73. Thus, human tumor-derived p53 mutants can associate with p73 not only physically but also functionally. These findings define a network involving mutant p53 and the various spliced isoforms of p73 that may confer upon tumor cells a selective survival advantage.

[1]  A. Jochemsen,et al.  Physical Interaction between Wilms Tumor 1 and p73 Proteins Modulates Their Functions* , 2000, The Journal of Biological Chemistry.

[2]  A. Yang,et al.  p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours , 2000, Nature.

[3]  Hua Lu,et al.  The N-Terminal Domain of p73 Interacts with the CH1 Domain of p300/CREB Binding Protein and Mediates Transcriptional Activation and Apoptosis , 2000, Molecular and Cellular Biology.

[4]  M. Oren Regulation of the p53 Tumor Suppressor Protein* , 1999, The Journal of Biological Chemistry.

[5]  W. Kaelin The p53 gene family , 1999, Oncogene.

[6]  K. Vousden,et al.  Mdm2 binds p73α without targeting degradation , 1999, Oncogene.

[7]  T. Davison,et al.  p73 and p63 Are Homotetramers Capable of Weak Heterotypic Interactions with Each Other but Not with p53* , 1999, The Journal of Biological Chemistry.

[8]  Jijie Gu,et al.  p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage , 1999, Nature.

[9]  Reuven Agami,et al.  Interaction of c-Abl and p73α and their collaboration to induce apoptosis , 1999, Nature.

[10]  Antonio Costanzo,et al.  The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage , 1999, Nature.

[11]  W. Kaelin,et al.  MDM2 Suppresses p73 Function without Promoting p73 Degradation , 1999, Molecular and Cellular Biology.

[12]  G Melino,et al.  Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants ε and ζ , 1999, Cell Death and Differentiation.

[13]  Christopher P. Crum,et al.  p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development , 1999, Nature.

[14]  H. Vogel,et al.  p63 is a p53 homologue required for limb and epidermal morphogenesis , 1999, Nature.

[15]  W. Kaelin The emerging p53 gene family. , 1999, Journal of the National Cancer Institute.

[16]  D. Tindall,et al.  Overexpression of the wild type p73 gene in human bladder cancer , 1999, Oncogene.

[17]  C. Prives,et al.  p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells , 1999, Molecular and Cellular Biology.

[18]  A. Levine,et al.  Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy , 1999, Oncogene.

[19]  C. Prives,et al.  The p53 pathway , 1999, The Journal of pathology.

[20]  F. Haluska,et al.  Mutational and expression analysis of the p73 gene in melanoma cell lines. , 1999, Cancer research.

[21]  J. Pipas,et al.  Adenovirus E4orf6 oncoprotein modulates the function of the p53-related protein, p73. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Roth,et al.  The large T antigen of simian virus 40 binds and inactivates p53 but not p73. , 1998, The Journal of general virology.

[23]  W. Stolz,et al.  Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas , 1998, Melanoma research.

[24]  N. Nomura,et al.  p73, a geme related to p53, is not mutated in esophageal carcinomas , 1998, International journal of cancer.

[25]  G. Melino,et al.  Two New p73 Splice Variants, γ and δ, with Different Transcriptional Activity , 1998, Journal of Experimental Medicine.

[26]  W. Kaelin,et al.  Viral Oncoproteins Discriminate between p53 and the p53 Homolog p73 , 1998, Molecular and Cellular Biology.

[27]  Moshe Oren,et al.  Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs , 1998, Oncogene.

[28]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.

[29]  M. Herlyn,et al.  p73beta, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. , 1998, International journal of oncology.

[30]  J. Cleveland,et al.  Activation of c-myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain , 1998, Molecular and Cellular Biology.

[31]  V. Rotter,et al.  Mutant p53 protein expression interferes with p53-independent apoptotic pathways , 1998, Oncogene.

[32]  D. Tindall,et al.  Activation of p73 silent allele in lung cancer. , 1998, Cancer research.

[33]  A. Nakagawara,et al.  Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. , 1998, Cancer Research.

[34]  K. Aldape,et al.  An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Nomoto,et al.  Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. , 1998, Cancer research.

[36]  W. Kaelin,et al.  p73 is a human p53-related protein that can induce apoptosis , 1997, Nature.

[37]  M. Oren Lonely No More: p53 Finds Its Kin in a Tumor Suppressor Haven , 1997, Cell.

[38]  A. Yang,et al.  Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.

[39]  A. Levine p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[40]  M. Oren,et al.  p53; from inductive signal to cellular effect. , 1997, Current opinion in genetics & development.

[41]  G. Thomas,et al.  P53 gene alterations in human tumors: perspectives for cancer control. , 1997, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[42]  N. Nomura,et al.  RN-tre specifically binds to the SH3 domain of eps8 with high affinity and confers growth advantage to NIH3T3 upon carboxy-terminal truncation. , 1996, Oncogene.

[43]  N. Nomura,et al.  RN-tre identifies a family of tre-related proteins displaying a novel potential protein binding domain. , 1996, Oncogene.

[44]  R. Evans,et al.  Ecdysone-inducible gene expression in mammalian cells and transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[45]  P. Pelicci,et al.  A protein-binding domain, EH, identified in the receptor tyrosine kinase substrate Eps15 and conserved in evolution. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[46]  E. Shaulian,et al.  Induction of apoptosis in HeLa cells by trans-activation-deficient p53. , 1995, Genes & development.

[47]  A. Levine,et al.  Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. , 1994, Genes & development.

[48]  A. Levine,et al.  Gain of function mutations in p53 , 1993, Nature Genetics.

[49]  E. Shaulian,et al.  Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding , 1992, Molecular and cellular biology.

[50]  S. Steinberg,et al.  p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. , 1992, Oncogene.

[51]  O. Halevy,et al.  p53 Mutations: Gains or losses? , 1991, Journal of cellular biochemistry.

[52]  A. Levine,et al.  Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells , 1979, Cell.

[53]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.